Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian T Ruff

Showing results (21-30 of 193) with videos related to

Pageof 20
Sort By:
Circulation|May 19, 2025
Factor XI Inhibition for Atrial Fibrillation: Where Do We Stand?Siddharth M Patel, Robert P Giugliano, Christian T Ruff
Chest|June 9, 2019
ResponseGregory Y H Lip, Christian T Ruff, Lisa Moores, et al.
Circulation|July 21, 2016
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal AgentsChristian T Ruff, Robert P Giugliano, Elliott M Antman
Circulation|October 26, 2020
Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism"Nicholas A Marston, Christian T Ruff, Marc S Sabatine
Plos One|March 18, 2021
Evaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillationKourosh Ravvaz, John A Weissert, Arshad Jahangir, et al.
Lancet (London, England)|July 8, 2014
New oral anticoagulants in patients with atrial fibrillation - Authors'replyChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
European Heart Journal. Acute Cardiovascular Care|October 16, 2018
The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trialsThomas A Zelniker, Christian T Ruff, Elliott M Antman, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 1, 2021
Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal ImpairmentClara Ting, Megan Rhoten, Jillian Dempsey, et al.
Journal of the American College of Cardiology|June 25, 2021
Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?Jan Steffel, Christian T Ruff, Elliott M Antman, et al.
Circulation. Cardiovascular Genetics|December 15, 2017
Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical TrialsKourosh Ravvaz, John A Weissert, Christian T Ruff, et al.
Pageof 20

Showing results (21-30 of 193) with videos related to

Sort By:
Pageof 20
Circulation|May 19, 2025
Factor XI Inhibition for Atrial Fibrillation: Where Do We Stand?Siddharth M Patel, Robert P Giugliano, Christian T Ruff
Chest|June 9, 2019
ResponseGregory Y H Lip, Christian T Ruff, Lisa Moores, et al.
Circulation|July 21, 2016
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal AgentsChristian T Ruff, Robert P Giugliano, Elliott M Antman
Circulation|October 26, 2020
Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism"Nicholas A Marston, Christian T Ruff, Marc S Sabatine
Plos One|March 18, 2021
Evaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillationKourosh Ravvaz, John A Weissert, Arshad Jahangir, et al.
Lancet (London, England)|July 8, 2014
New oral anticoagulants in patients with atrial fibrillation - Authors'replyChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
European Heart Journal. Acute Cardiovascular Care|October 16, 2018
The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trialsThomas A Zelniker, Christian T Ruff, Elliott M Antman, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 1, 2021
Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal ImpairmentClara Ting, Megan Rhoten, Jillian Dempsey, et al.
Journal of the American College of Cardiology|June 25, 2021
Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?Jan Steffel, Christian T Ruff, Elliott M Antman, et al.
Circulation. Cardiovascular Genetics|December 15, 2017
Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical TrialsKourosh Ravvaz, John A Weissert, Christian T Ruff, et al.
Pageof 20